State Street Exits Allogene Therapeutics Stake
Ticker: ALLO · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Sentiment | bearish |
Complexity: simple
Sentiment: bearish
Topics: institutional-selling, ownership-change, biotech
TL;DR
**State Street just dumped its Allogene Therapeutics shares, watch out for price drops.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Allogene Therapeutics, Inc. common stock as of December 31, 2023. This filing is an 'exit filing,' meaning State Street no longer holds a reportable stake (above 5%) in Allogene Therapeutics. For investors, this matters because a large institutional investor has reduced its position, which could signal a change in their outlook on the company's future prospects or simply a portfolio rebalancing.
Why It Matters
When a major institutional investor like State Street Corporation reduces its stake in a company, it can influence market sentiment and potentially lead to a decrease in the stock price due to perceived lack of institutional confidence.
Risk Assessment
Risk Level: medium — The exit of a large institutional investor could signal underlying concerns or simply a portfolio rebalancing, creating uncertainty for current and potential investors.
Analyst Insight
A smart investor would monitor Allogene Therapeutics' stock price and news closely for any further institutional selling or new developments that might explain State Street's exit. This could be a signal to re-evaluate one's own position or to wait for more clarity before investing.
Key Players & Entities
- State Street Corporation (company) — the reporting person exiting its stake
- Allogene Therapeutics, Inc. (company) — the subject company whose stock was held
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- Allogene Therapeutics' stock price may experience downward pressure in the short term. (Allogene Therapeutics, Inc.) — medium confidence, target: 3 months
- Other institutional investors might re-evaluate their positions in Allogene Therapeutics. (Allogene Therapeutics, Inc.) — low confidence, target: 6 months
FAQ
What is the purpose of this specific SC 13G/A filing by State Street Corporation?
This SC 13G/A is an 'EXIT FILING,' as explicitly stated in the document, indicating that State Street Corporation no longer holds a reportable ownership percentage (typically above 5%) in Allogene Therapeutics, Inc. as of December 31, 2023.
Which company is the subject of this filing, and what is its primary business?
The subject company is Allogene Therapeutics, Inc. (CIK: 0001737287). Its Standard Industrial Classification (SIC) is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]', indicating it operates in the biotechnology or pharmaceutical sector.
What was the 'Date of Event' that triggered this filing?
The 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT' was December 31, 2023, as specified in the filing.
What is the CUSIP number for the class of securities mentioned in the filing?
The CUSIP number for the Common Stock of Allogene Therapeutics, Inc. is 019770106, as listed on the cover page of the filing.
Under which SEC rule was this Schedule 13G filed?
This Schedule 13G was filed under 'RULE 13D-1 (B)', as indicated by the 'X' next to the rule designation on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Allogene Therapeutics, Inc. (ALLO).